801
Participants
Start Date
June 30, 2009
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
KETOPROFEN(RP19583)
Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
KETOPROFEN(RP19583)
Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Placebo
Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Sanofi-Aventis Administrative Office, Cairo
Sanofi-Aventis Administrative Office, Helsinki
Sanofi-Aventis Administrative Office, Paris
Sanofi-Aventis Administrative Office, Frankfurt
Sanofi-Aventis Administrative Office, Col. Coyoacan
Sanofi-Aventis Administrative Office, Moscow
Sanofi-Aventis Administrative Office, Barcelona
Lead Sponsor
Sanofi
INDUSTRY